@article{f8c721eae1c84b8e984ae9174129ff16,
title = "AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease",
abstract = "This report summarizes the presentations, discussions, and recommendations of the most recent American Geriatrics Society and National Institute on Aging research conference, “Cancer and Cardiovascular Disease,” on October 18–19, 2021. The purpose of this virtual meeting was to address the interface between cancer and heart disease, which are the two leading causes of death among older Americans. Age-related physiologic changes are implicated in the pathogenesis of both conditions. Emerging data suggest that cancer-related cardiovascular disease (CVD) involves disrupted cell signaling and cellular senescence. The risk factors for CVD are also risk factors for cancer and an increased likelihood of cancer death, and people who have both cancer and CVD do more poorly than those who have only cancer or only CVD. Issues addressed in this bench-to-bedside conference include mechanisms of cancer and CVD co-development in older adults, cardiotoxic effects of cancer therapy, and management of comorbid cancer and CVD. Presenters discussed approaches to ensure equitable access to clinical trials and health care for diverse populations of adults with CVD and cancer, mechanisms of cancer therapy cardiotoxicity, and management of comorbid CVD and cancer, including the role of patient values and preferences in treatment decisions. Workshop participants identified many research gaps and questions that could lead to an enhanced understanding of comorbid CVD and cancer and to better and more equitable management strategies.",
keywords = "aging, cancer, cardiotoxicity, cardiovascular disease",
author = "Supriya Mohile and Blaum, {Caroline S.} and Abadir, {Peter M.} and William Dale and Forman, {Daniel E.} and Chunkit Fung and Holmes, {Holly M.} and Javid Moslehi and Mustian, {Karen M.} and Rich, {Michael W.} and Whitson, {Heather E.}",
note = "Funding Information: We thank Deborah Berlyne, PhD, for her editorial assistance with the manuscript. We also thank the moderators and presenters at this meeting whose remarks are summarized in this report: Opening Remarks: Supriya Mohile, MD, MS, University of Rochester; Daniel E. Forman, MD, University of Pitetsburgh; Jessica Scott, PhD, Memorial Sloan Kettering Cancer Center Mechanisms of Co-Development of Cancer and Cardiovascular Disease in an Aging Population: Michael W. Rich, MD, Washington University in St. Louis; Nir Barzilai, MD, Albert Einstein College of Medicine; Lorna Haughton McNeill, PhD, MPH, MD Anderson Cancer Center; Pradeep Natarajan, MD, MMSc, Massachusetts General Hospital; Anju Nohria, MMSc, MD, MSc, Brigham and Women's Hospital Cardiotoxicity in the Older Cancer Survivor: Chunkit Fung, MD, University of Rochester; Aarti H. Asnani, MD, Beth Israel Deaconess Medical Center; Brian Colwell Jensen, MD, University of North Carolina at Chapel Hill; Daniel Lenihan, MD, International Cardio-Oncology Society; Nonniekaye Shelburne, CRNP, MS, National Cancer Institute Management of Comorbid Cancer and Heart Disease and Challenges in Medical Decision-Making: William Dale, MD, PhD, City of Hope National Medical Center; Anne Blaes, MD, University of Minnesota; John Dodson, MD, MPH, New York University; Holly M. Holmes, MD, MS, University of Texas Health Science Center at Houston; Beverly Canin, Breast Cancer Options Moderated Discussion: Karen Mustian, PhD, MS, MPH, University of Rochester Medical Center Funding Information: This work was supported by the American Geriatrics Society and a grant from the National Institute on Aging at the National Institutes of Health (grant number 5U13AG054139). Funding Information: JM has served on advisory boards for Pfizer, Novartis, Bristol‐Myers Squibb, Deciphera, Audentes Pharmaceuticals, Takeda, Myokardia, AstraZeneca, GlaxoSmithKline, Boston Biomedical, ImmunoCore, Janssen, Myovant, Silverback Therapeutics, Amgen, Kurome Therapeutics, Kiniska Pharmaceuticals, Daiichi Sankyo, CRC Oncology, BeiGene, Star Therapeutics, ProteinQure, Pharmacyclics, Mallinckrodt Pharmaceuticals, Boehringer, and Cytokinetics, and is supported by is supported by National Institutes of Health grants (R01HL141466, R01HL155990, R01HL156021). HMH is funded by Healthcare Services Corporation (Blue Cross/Blue Shield), the National Institute on Aging, and the National Center to Advance Translational Sciences. Supriya Mohile, Caroline S. Blaum, Heather E. Whitson, Peter M. Abadir, William Dale, Daniel E. Forman, Chunkit Fung, Karen M. Mustian, and Michael W. Rich have no conflicts to report. Funding Information: This work was supported by the American Geriatrics Society and a grant (5U13AG054139) from the National Institute on Aging at the National Institutes of Health. Publisher Copyright: {\textcopyright} 2022 The American Geriatrics Society.",
year = "2022",
month = oct,
doi = "10.1111/jgs.17921",
language = "English",
volume = "70",
pages = "2764--2774",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
number = "10",
}